Identification of BACE2 as an avid -amyloid-degrading protease

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Abdul Hay, Samer O ^a   Sahara, Tomoko ^a   McBride, Melinda ^a   Kang, Dongcheul ^a   Leissring, Malcolm A ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

site APP cleaving enzyme 1; site APP cleaving enzyme 2; Alzheimer disease; Amyloid protein; Functional screen; Gene therapy; Protease; Proteolytic degradation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 2; ENDOTHELIN CONVERTING ENZYME; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; PROTEINASE;

ANIMAL CELL; ARTICLE; BIOCATALYSIS; CELL CULTURE; CONTROLLED STUDY; ENZYME ASSAY; ENZYME LOCALIZATION; GENETIC TRANSFECTION; HUMAN; HUMAN GENOME; KINETICS; NONHUMAN; PH; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; AMYLOID; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; CELLS, CULTURED; HUMANS; INSULYSIN; METALLOENDOPEPTIDASES; NEPRILYSIN;

EID: 84867583311     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-46     Document Type: Article

References (46)

1. Translating cell biology into therapeutic advances in Alzheimer's disease. Selkoe DJ, Nature 1999 399 23 31 10392577
2. Beta-secretase (BACE) as a drug target for Alzheimer's disease. Vassar R, Adv Drug Deliv Rev 2002 54 1589 1602 10.1016/S0169-409X(02)00157-6 12453676
3. The secretases: enzymes with therapeutic potential in Alzheimer disease. De Strooper B, Vassar R, Golde T, Nat Rev Neurol 2010 6 99 107 10.1038/nrneurol.2009.218 20139999
4. The gamma-secretase complex: membrane-embedded proteolytic ensemble. Wolfe MS, Biochemistry 2006 45 7931 7939 10.1021/bi060799c 16800619
5. Neuroscience: Alzheimer's disease. Mucke L, Nature 2009 461 895 897 10.1038/461895a 19829367
6. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Eckman EA, Eckman CB, Biochem Soc Trans 2005 33 1101 1105 10.1042/BST20051101 16246055
7. Degradation of amyloid- protein. Leissring MA, Saido TC, The biology of Alzheimer disease Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, Selkoe DJ, Mandelkow E, Holtzman DM, 2011 387 404
8. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ, Science 2010 330 1774 10.1126/science.1197623 21148344
9. The ACs of A-cleaving proteases. Leissring MA, J Biol Chem 2008 283 29645 29649 10.1074/jbc.R800022200 18723506
10. The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region. Acquati F, Accarino M, Nucci C, Fumagalli P, Jovine L, Ottolenghi S, Taramelli R, FEBS Lett 2000 468 59 64 10.1016/S0014-5793(00)01192-3 10683441
11. Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity. Shi XP, Tugusheva K, Bruce JE, Lucka A, Wu GX, Chen-Dodson E, Price E, Li Y, Xu M, Huang Q, et al. J Biol Chem 2003 278 21286 21294 10.1074/jbc.M209859200 12665519
12. Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells. Basi G, Frigon N, Barbour R, Doan T, Gordon G, McConlogue L, Sinha S, Zeller M, J Biol Chem 2003 278 31512 31520 10.1074/jbc.M300169200 12801932
13. BACE2 functions as an alternative alpha-secretase in cells. Yan R, Munzner JB, Shuck ME, Bienkowski MJ, J Biol Chem 2001 276 34019 34027 10.1074/jbc.M105583200 11423558
14. A non-amyloidogenic function of BACE-2 in the secretory pathway. Fluhrer R, Capell A, Westmeyer G, Willem M, Hartung B, Condron MM, Teplow DB, Haass C, Walter J, J Neurochem 2002 81 1011 1020 10.1046/j.1471-4159.2002.00908.x 12065613
15. ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. Hussain I, Powell DJ, Howlett DR, Chapman GA, Gilmour L, Murdock PR, Tew DG, Meek TD, Chapman C, Schneider K, et al. Mol Cell Neurosci 2000 16 609 619 10.1006/mcne.2000.0884 11083922
16. BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H, Proc Natl Acad Sci USA 2000 97 9712 9717 10.1073/pnas.160115697 10931940
17. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. Sun X, He G, Song W, FASEB J 2006 20 1369 1376 10.1096/fj.05-5632com 16816112
18. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ, J Biol Chem 1998 273 32730 32738 10.1074/jbc.273.49.32730 9830016
19. Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. Qiu WQ, Ye Z, Kholodenko D, Seubert P, Selkoe DJ, J Biol Chem 1997 272 6641 6646 10.1074/jbc.272.10.6641 9045694
20. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ, J Neurosci 2000 20 1657 1665 10684867
21. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. Science 1999 286 735 741 10.1126/science.286.5440.735 10531052
22. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ, Proc Natl Acad Sci USA 2003 100 6382 6387 10.1073/pnas. 1037392100 12740439
23. Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. Leissring MA, Lu A, Condron MM, Teplow DB, Stein RL, Farris W, Selkoe DJ, J Biol Chem 2003 278 37314 37320 10.1074/jbc.M305627200 12867419
24. Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. Fluhrer R, Multhaup G, Schlicksupp A, Okochi M, Takeda M, Lammich S, Willem M, Westmeyer G, Bode W, Walter J, Haass C, J Biol Chem 2003 278 5531 5538 10.1074/jbc.M211485200 12471021
25. Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. Nichols MR, Moss MA, Reed DK, Lin WL, Mukhopadhyay R, Hoh JH, Rosenberry TL, Biochemistry 2002 41 6115 6127 10.1021/bi015985r 11994007
26. Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. Rangachari V, Moore BD, Reed DK, Sonoda LK, Bridges AW, Conboy E, Hartigan D, Rosenberry TL, Biochemistry 2007 46 12451 12462 10.1021/bi701213s 17910477
27. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. Eckman EA, Reed DK, Eckman CB, J Biol Chem 2001 276 24540 24548 10.1074/jbc.M007579200 11337485
28. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Perez A, Morelli L, Cresto JC, Castano EM, Neurochem Res 2000 25 247 255 10.1023/A:1007527721160 10786709
29. Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking. Fuentealba RA, Liu Q, Zhang J, Kanekiyo T, Hu X, Lee JM, LaDu MJ, Bu G, PLoS One 2010 5 11884 10.1371/journal.pone.0011884 20686698
30. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, et al. J Biol Chem 2005 280 30797 30806 10.1074/jbc.M505249200 15987683
31. BACE1 and BACE2 enzymatic activities in Alzheimer's disease. Ahmed RR, Holler CJ, Webb RL, Li F, Beckett TL, Murphy MP, J Neurochem 2010 112 1045 1053 10.1111/j.1471-4159.2009.06528.x 19968762
32. Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Cheon MS, Dierssen M, Kim SH, Lubec G, Amino Acids 2008 35 339 343 10.1007/s00726-007-0618-9 18163181
33. BACE2 expression increases in human neurodegenerative disease. Holler CJ, Webb RL, Laux AL, Beckett TL, Niedowicz DM, Ahmed RR, Liu Y, Simmons CR, Dowling AL, Spinelli A, et al. Am J Pathol 2012 180 337 350 10.1016/j.ajpath. 2011.09.034 22074738
34. Elevated expression of beta-site amyloid precursor protein cleaving enzyme 2 in brains of patients with Down syndrome. Motonaga K, Itoh M, Becker LE, Goto Y, Takashima S, Neurosci Lett 2002 326 64 66 10.1016/S0304-3940(02) 00287-2 12052539
35. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain. Stockley JH, O'Neill C, Biochem Soc Trans 2007 35 574 576 10.1042/BST0350574 17511655
36. Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain. Stockley JH, Ravid R, O'Neill C, FEBS Lett 2006 580 6550 6560 10.1016/j.febslet.2006.10.076 17113083
37. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J, Nat Med 2003 9 453 457 10.1038/nm838 12612547
38. Gene therapy in Alzheimer's disease-potential for disease modification. Nilsson P, Iwata N, Muramatsu S, Tjernberg LO, Winblad B, Saido TC, J Cell Mol Med 2010 14 741 757 10.1111/j.1582-4934.2010.01038.x 20158567
39. Intracellular amyloid-beta in Alzheimer's disease. LaFerla FM, Green KN, Oddo S, Nat Rev Neurosci 2007 8 499 509 10.1038/nrn2168 17551515
40. Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Zhao J, Li L, Leissring MA, Mol Neurodegener 2009 4 4 10.1186/1750-1326-4-4 19144176
41. Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. Turner AJ, Biochem Soc Trans 2003 31 723 727 12773192
42. Nonsteroidal anti-inflammatory drugs and ectodomain shedding of the amyloid precursor protein. Leuchtenberger S, Maler J, Czirr E, Ness J, Lichtenthaler SF, Esselmann H, Pietrzik CU, Wiltfang J, Weggen S, Neurodegener Dis 2009 6 1 8 18349521
43. Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. Chen F, Eckman EA, Eckman CB, FASEB J 2006 20 1269 1271 10.1096/fj.05-5530fje 16636099
44. NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. Abdul-Hay SO, Luo J, Ashghodom RT, Thatcher GR, J Neurochem 2009 111 766 776 10.1111/j.1471-4159. 2009.06353.x 19702655
45. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE, J Neurosci 2006 26 11923 11928 10.1523/JNEUROSCI.2795-06.2006 17108166
46. Modification of amyloid-beta(1-40) by a protease inhibitor creates risk of error in mass spectrometric quantitation of amyloid-beta(1-42). Conboy JJ, Wood KG, Lame ME, Durham RA, Geoghegan KF, Anal Biochem 2008 382 147 149 10.1016/j.ab.2008.07.033 18706385